

RNS Number : 9420J
Redx Pharma plc
10 April 2024

REDX PHARMA PLC

("Redx" or the "Company")

Update on Broking Arrangements

Alderley Park, UK, 10 April 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that further to the announcement on 2 April 2024 with respect to the proposed cancellation of the admission of the Company's ordinary shares of 1 pence each to trading on AIM and re-registration as a private limited company, WG Partners LLP will cease to be the Company's joint broker with immediate effect, and Panmure Gordon (UK) Limited will act as the Company's sole broker.

For further information, please contact:

Redx Pharma Plc T: +44 (0)1625 469 918

UK Headquarters

Caitlin Pearson, Head of Communications

ir@redxpharma.com

SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550

Matt Davis/Adam Dawes

Panmure Gordon (UK) Limited (Broker) T: +44 (0)207 886 2500

Rupert Dearden/Freddy Crossley/Emma Earl

FTI Consulting T: +44 (0)203 727 1000

Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company expects a number of data points during 2024 including from lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), in development for interstitial lung disease and currently undertaking a Phase 2a trial for idiopathic pulmonary fibrosis (IPF). The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1 development and is expected to report healthy volunteer data; and Redx's lead oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004), being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data, following which Redx will seek a partner for ongoing development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPFKLLBZZLFBBQ